In September 2006, Lectus Therapeutics relocated its corporate headquarters and research facility to the Babraham Research Campus, Cambridge, UK
Lectus, originally based in Bristol, UK, will run all research operations as well as commercial and financial activities from the new location.
Lectus's relocation to Cambridge forms an important part of its strategy in developing a robust infrastructure to reflect the growth of its research and development activities following its successful £8.2m Series A financing.
Lectus has been operating part of its research activities at Babraham since April 2006, following its acquisition of NeuroServe, an electrophysiology company providing research facilities important in the development of Lectus's ion channel modulators.
Lectus has now taken steps to integrate its entire commercial and research activities, including the exploitation of its proprietary proteomics research engine, Leptics, to the Cambridge biotechnology cluster.
Roland Kozlowski, CEO of Lectus, commented: "Our move to the new facility at the Babraham Research Campus represents the next step in the implementation of our strategy for growth.
"With this move, we will benefit from improved research facilities and exceptional local infrastructure and will be in an excellent position to progress our next-generation ion channel drugs, for treatment of pain and urinary incontinence, towards the clinic."
